Sunresin New Materials Co (300487) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
19 Aug, 2026Executive summary
Revenue for H1 2026 reached ¥1.378 billion, up 10.47% year-over-year; net profit attributable to shareholders was ¥420.52 million, down 5.40% year-over-year, mainly due to ¥81.05 million in forex losses.
Excluding forex losses, net profit would have increased by approximately 17.99% year-over-year.
Gross margin improved to 53.28%, up 2.02 percentage points, driven by higher-margin segments like life sciences and metal resources.
Cash flow from operations rose 53.58% to ¥442.99 million.
Financial highlights
Operating income: ¥1.378 billion (+10.47% YoY); net profit: ¥420.52 million (-5.40% YoY).
Gross margin: 53.28% (+2.02 ppt YoY); net assets: ¥4.73 billion (+7.66% from year-end 2025).
Basic/diluted EPS: ¥0.83 (-5.68% YoY); ROE: 9.09% (-1.63 ppt YoY).
Total assets: ¥6.91 billion (+4.81% from year-end 2025); asset-liability ratio: 31.65%.
Non-recurring gains: ¥6.89 million, mainly from government subsidies and asset disposals.
Outlook and guidance
Continued focus on high-margin segments (life sciences, metal resources, ultrapure water).
Ongoing expansion in international markets and R&D investment in new materials and technologies.
Construction of a new life sciences high-end materials park is underway to boost future capacity.
Latest events from Sunresin New Materials Co
- Record revenue and profit, robust segment growth, and strong international expansion.300487
Q2 2024 - Record revenue and profit, strong core growth, and overseas sales up 45.1% year-over-year.300487
Q4 2024 - Revenue and net profit rose double digits year-over-year, with robust cash flow and expansion.300487
Q3 2024 - Net profit rose 10% to ¥444.5 million on improved margins and strong cash flow.300487
Q2 2025 - Net profit up 14.18% year-over-year despite 8.58% revenue drop; cash flow surged.300487
Q1 2025 - Record revenue and profit growth driven by core segments and robust R&D investment.300487
Q4 2025 - Q3 saw double-digit revenue growth and new investment in a life sciences materials park.300487
Q3 2025 - Revenue up 5.24%, net profit down 5.81%, and operating cash flow up 36.59% year-over-year.300487
Q1 2026